Repare Therapeutics Inc
NASDAQ: RPTX · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-01-28
Repare Therapeutics Inc (RPTX) Financial statements
SEC filings — annual and quarterly data.
Margin trends — annual
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2017 | $0.00 | $-7.80M | — | — | — |
| 2018 | $0.00 | $-14.28M | — | — | — |
| 2019 | $0.00 | $-27.22M | — | — | — |
| 2020 | $135000.00 | $-53.42M | -28,622.22% | -40,223.70% | -39,568.15% |
| 2021 | $7.60M | $-106.91M | -1,055.97% | -1,429.74% | -1,406.68% |
| 2022 | $131.83M | $-29.05M | 11.46% | -15.02% | -22.03% |
| 2023 | $51.13M | $-93.80M | 74.11% | -227.30% | -183.44% |
| 2024 | $53.48M | $-84.69M | 74.98% | -174.88% | -158.37% |
Frequently asked questions
What is Repare Therapeutics Inc's revenue?
Repare Therapeutics Inc's trailing twelve-month revenue is $11.87M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is RPTX?
In its most recent fiscal year, RPTX ran a gross margin of 74.98%, an operating margin of -174.88%, and a net margin of -158.37%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does RPTX generate?
RPTX produced $-76.44M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.